Corticotropin-releasing hormone (CRH) and CRH receptor 1 gene expression in vitiligo

Shaker, Olfat G.; El‐Tahlawi, Samar; Tawfic, Shereen O.; El-Tawdy, Amira; Bedair, Nermeen Ibrahim

doi:10.1111/ced.12907

Cited by 8 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shaker et al demonstrated significantly higher mean expressions of CRH, and corticotropin releasing hormone receptor 1 (CRHR-1) detected by real-time polymerase chain reaction (PCR) in the depigmented lesions than in control skin. Moreover, significantly higher expressions of CRH and CRH-R1 were correlated with a stress scale 12 . In the current study, there was a positive correlation between serum CRH level and GAD-7.…”

Section: Discussionmentioning

confidence: 90%

“…Some authors described the cutaneous expression of CRH and its’ receptor, which is detected by performing a skin biopsy. The authors found a significant increase in the expression of CRH and corticotropin releasing hormone receptor 1 (CRH-R1) in both damaged and intact skin of vitiligo patients that were exposed to stress 12 . Besides, the in vitro studies and clinical evidence of direct and indirect pro-inflammatory action of CRH were reported for vitiligo.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Associations between serum levels of brain-derived neurotrophic factor, corticotropin releasing hormone and mental distress in vitiligo patients

Kussainova

Kassym

Akhmetova

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Vitiligo is clinically characterized by the appearance of non-symptomatic depigmented macules, but the disorder is highly correlated with a wide range of psychiatric disorders and psychological problems. The aim of our study was to investigate serum brain-derived neurotrophic factor (BDNF) and corticotropin releasing hormone (CRH) levels in vitiligo patients and healthy controls in relation to the observed symptoms of depression and anxiety disorders. This study comprised 96 vitiligo patients and 96 healthy controls who filled out the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) scales. Serum levels of BDNF and CRH were measured using enzyme-linked immunosorbent assay (ELISA) technique. There was a significant increase of depression and anxiety scores in vitiligo patients as compared with healthy controls (P < 0.05). The serum levels of BDNF were significantly lower in vitiligo patients than in healthy individuals (Z = 4.002; P < 0.001), while the serum levels of CRH were markedly higher in cases than those in controls (Z = 3.764; P < 0.001). The significant positive correlations between serum CRH levels and GAD-7, PHQ-9 scores were observed. However, the aforementioned psychometric scales did not correlate significantly with serum BDNF level. Vitiligo is associated with the depression and is closely linked with lower BDNF levels.

show abstract

Section: Discussionmentioning

confidence: 90%

mentioning

confidence: 99%

Associations between serum levels of brain-derived neurotrophic factor, corticotropin releasing hormone and mental distress in vitiligo patients

Kussainova

Kassym

Akhmetova

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Alcohol dependence or abuse was reported in three studies (2.4–7.6%) [ 22 , 57 , 137 ]. Patients were affected by adjustment disorders, such as stress associated with vitiligo and worry about spread (12 studies, 4–93.9%) [ 13 , 30 , 32 , 40 , 100 , 109 , 113 , 114 , 131 , 141 , 142 , 149 ], and also experienced aspects of self-consciousness, including embarrassment (eight studies, 24–66.7%) [ 13 , 32 , 131 – 133 , 135 , 142 , 145 ] and low self-esteem (four studies, 6.2–72.7%) [ 32 , 68 , 69 , 141 ]. Relationship difficulties including sexual dysfunction were reported over a wide range of patients (ten studies, 2.0–81.8%) [ 32 , 43 , 97 , 109 , 131 , 132 , 135 , 154 , 155 , 167 ].…”

Section: Resultsmentioning

confidence: 99%

Psychosocial Effects of Vitiligo: A Systematic Literature Review

et al. 2021

View full text Add to dashboard Cite

Background Patients with vitiligo experience reduced quality of life. Objective To comprehensively describe the available evidence for psychosocial burden in vitiligo. Methods A systematic review of observational studies and clinical trials identified using PubMed, EMBASE, Scopus, and the Cochrane databases was performed through 1 March, 2021, to assess psychosocial comorbidities in vitiligo. Two independent reviewers performed an assessment of articles and extracted data for qualitative synthesis. Results Included studies (N = 168) were published between 1979 and 1 March, 2021; 72.6% were published since 2010. Disorders including or related to depression (41 studies, 0.1-62.3%) and anxiety (20 studies, 1.9-67.9%) were the most commonly reported. The most prevalent psychosocial comorbidities were feelings of stigmatization (eight studies, 17.3-100%), adjustment disorders (12 studies, 4-93.9%), sleep disturbance (seven studies, 4.6-89.0%), relationship difficulties including sexual dysfunction (ten studies, 2.0-81.8%), and avoidance or restriction behavior (12.5-76%). The prevalence of most psychosocial comorbidities was significantly higher vs healthy individuals. Factors associated with a significantly higher burden included female sex, visible or genital lesions, age < 30 years (particularly adolescents), and greater body surface area involvement, among others. The most commonly reported patient coping strategy was lesion concealment. Limitations Available studies were heterogeneous and often had limited details; additionally, publication bias is possible. Conclusions The results of this systematic review show that vitiligo greatly affects psychosocial well-being. The extent of psychosocial comorbidities supports the use of multidisciplinary treatment strategies and education to address the vitiligoassociated burden of disease. Protocol Registration PROSPERO (CRD42020162223).

show abstract

“…It has been shown that there was a significant increase in the serum level of cortisol in patients with active vitiligo compared with that in those with either stable vitiligo or a healthy control group 47 . This may be related to high levels of depression and psychogenic stress in vitiligo patients, which can stimulate the secretion of corticotropin-releasing hormone, thus inducing or exacerbating depigmented lesions [48][49][50] . Our findings are consistent with previous reports showing that cortexolone levels gradually decreased as the disease improved.…”

Section: Discussionmentioning

confidence: 99%

Urinary metabolomic investigations in vitiligo patients

Liu

Qian

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Urinary metabolomics is a useful non-invasive tool for large-scale screening of disease-related metabolites. However, no comprehensive urinary metabolomic analysis of vitiligo is presently available. To investigate the urine metabolic pattern of vitiligo patients, we conducted a combined cross-sectional and prospective self-control cohort study and an untargeted urinary metabolomic analysis. In the cross-sectional study, 295 vitiligo patients and 192 age‐ and sex‐matched controls were enrolled, and 71 differential metabolites between two groups were identified. Pathway enrichment analysis revealed that drug metabolism-cytochrome P450, biopterin metabolism, vitamin B9 (folate) metabolism, selenoamino acid metabolism, and methionine and cysteine metabolism showed significant enrichment in vitiligo patients compared with the status in healthy controls. In the self-control cohort, 46 active vitiligo patients were recruited to analyse the urinary metabolic signatures after treatment. All of these patients were asked to undertake follow-up visits every 2 months three times after first consulting and the disease stage was evaluated compared with that at the last visit. Folate metabolism, linoleate metabolism, leukotriene metabolism, alkaloid biosynthesis, and tyrosine metabolism were predicted to be involved in vitiligo activity. Our study is the first attempt to reveal urinary metabolic signatures of vitiligo patients and provides new insights into the metabolic mechanisms of vitiligo.

show abstract

Corticotropin-releasing hormone (CRH) and CRH receptor 1 gene expression in vitiligo

Abstract: We conclude that CRH and CRHR-1 are altered by psychological stress and play an important role in the pathogenesis of vitiligo.

Cited by 8 publications

References 26 publications

Associations between serum levels of brain-derived neurotrophic factor, corticotropin releasing hormone and mental distress in vitiligo patients

Associations between serum levels of brain-derived neurotrophic factor, corticotropin releasing hormone and mental distress in vitiligo patients

Psychosocial Effects of Vitiligo: A Systematic Literature Review

Urinary metabolomic investigations in vitiligo patients

Contact Info

Product

Resources

About